PIPELINE > TRIAL OVERVIEW
PI3Kα Inhibitor
LOXO-783
- Type of Alteration(s)
Point Mutation
Alteration(s) of InterestPIK3CA H1047R
Methodology
Key Considerations
Sanger Sequencing- Can detect all possible PIK3CA mutations within an exon
- Detection may require higher tumor content than PCR-based assays
PCR-Based- Will detect selected mutations but may miss novel PIK3CA alterations
NGS (Tissue)- Should have full coverage of Exon 20
NGS (cfDNA)- Useful when tissue biopsy sample is limited/unavailable
- Higher false negative rate than tissue-based NGS testing
Single base extension/MassArray- Will detect selected mutations but may miss novel PIK3CA alterations
References
- Samuels Y, et al. Science. 2004;304(5670):554.
For information on trial enrollment, locations, and more, call
1-800-545-5979.
or visit www.clinicaltrials.gov for more information on this trial
This website was commissioned by Lilly Medical and is indicated to be used by HCPs for medical, scientific, and educational purposes.
The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and become commercially available for the uses being investigated. The information provided about new molecules being studied is for scientific information exchange purposes only with no commercial intent.
